基于条件推断树模型预测乳腺超声检出的非肿块型病变的癌症风险
本研究为单中心回顾性研究,纳入2012至2019年间503个乳腺超声检出的非肿块型病变(NML),按70/30随机分为训练集和测试集,利用条件推断树(CTREE)基于年龄、症状、病灶大小及超声特征构建恶性风险预测模型。多因素分析显示年龄、局灶性肿块效应、腺体-脂肪界面不清、地理状及斑驳状模式、钙化与恶性相关;模型在测试集AUC为0.797,可将BI-RADS类别重新分层以辅助临床决策。
要点
- 腺体-脂肪界面不清、局灶性肿块效应、地理状或斑驳状模式及钙化是乳腺超声NML最强的恶性影像预测因子。
- CTREE模型在测试集AUC为0.797,可将NML分为6个风险组,对BI-RADS分类进行再分层。
- 该模型可能通过评估恶性相对概率辅助患者分层,支持临床决策和循证管理,有望减少不必要的活检。
核心结论
- CTREE模型能有效辅助解读和管理超声检出的乳腺NML,通过细化癌症风险分层克服BI-RADS的局限性。
研究设计与样本
- 单中心回顾性研究,连续纳入2012至2019年间乳腺超声检出的503个NML(498例患者),随机按70/30分为训练集和测试集,以病理或>2年随访为参考标准,采用多因素分析和条件推断树(CTREE)构建预测模型。
关键影像表现/征象
- NML伴局灶性肿块效应(OR=3.03,95%CI 1.59-5.81,p=0.001)与恶性相关。
- 腺体-脂肪界面不清(OR=4.23,95%CI 2.31-7.73,p<0.001)与恶性相关。
- 地理状模式(OR=3.47,95%CI 1.20-10.8,p=0.022)和斑驳状模式(OR=3.67,95%CI 1.32-10.21,p=0.013)与恶性相关。
- 钙化(OR=2.15,95%CI 1.16-4.01,p=0.016)与恶性相关。
- 年龄(OR=1.08,95%CI 1.06-1.11,p<0.001)与恶性相关。
诊断标准与关键数值
- 基于腺体-脂肪界面状态、结构模式、总体形态和钙化,CTREE模型将个体分为6个风险组。
- 预测模型在测试集的AUC为0.797。
- CTREE模型可将BI-RADS类别重新分类为具有不同恶性概率的亚组。
临床应用与阅片要点
- 阅片时关注NML的腺体-脂肪界面是否清晰、有无局灶性肿块效应、结构模式(地理状或斑驳状)及钙化,这些是恶性最强预测因子。
- CTREE模型可对BI-RADS类别进行再分层,提供不同恶性概率的亚组,可能有助于减少不必要的活检。
- 该模型可能通过确定恶性相对概率辅助患者分层,支持临床决策和循证管理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To generate and validate a prediction model based on imaging features for cancer risk of non-mass lesions (NMLs) detected on breast ultrasound (US).
METHODS: In this single-center study, consecutive women with 503 NMLs detected on breast US between 2012 and 2019 were retrospectively identified. The lesions were randomly assigned to the training or testing dataset with a 70/30 split. Age, symptoms, lesion size, and US features were collected. Multivariate analyses were employed to identify risk factors associated with malignancy. The predictive model was developed by using conditional inference trees (CTREE).
RESULTS: There were 498 patients (50.9 ± 13.29 years; range, 22-88 years) with 503 NMLs with histopathologic results or > 2-year follow-up, including 224 (44.5%) benign and 279 (55.5%) malignant lesions. At multivariate analysis, age (odds ratio (OR) = 1.08, 95% confidence interval (CI), 1.06-1.11, p < 0.001), NMLs with focal mass effect (OR = 3.03, 95% CI, 1.59-5.81, p = 0.001), indistinct glandular-fat interface (GFI) (OR = 4.23, 95% CI, 2.31-7.73, p < 0.001), geographic (OR = 3.47, 95% CI, 1.20-10.8, p = 0.022) and mottled (OR = 3.67, 95% CI, 1.32-10.21, p = 0.013) patterns, and calcifications (OR = 2.15, 95% CI, 1.16-4.01, p = 0.016) were associated with malignancy. The GFI status, architectural patterns, general morphology, and calcifications were consistently identified as the strongest US predictors of malignancy using CTREE analysis. Based on these factors, individuals were stratified into six risk groups. The predictive model showed an area under the curve of 0.797 in the testing dataset.
CONCLUSION: The CTREE model efficiently aids in interpreting and managing ultrasound-detected breast NMLs, overcoming BI-RADS limitations by refining cancer risk stratification.
CLINICAL RELEVANCE STATEMENT: The CTREE model allows for the reclassification of BI-RADS categories into subgroups with varying malignancy probabilities, thus providing a valuable enhancement to the BI-RADS assessment for the diagnosis of ultrasound-detected NMLs, with the potential to minimize unnecessary biopsies.
KEY POINTS: • The indistinct glandular-fat interface (GFI) status, NML with focal mass effect, geographic or mottled patterns, and calcifications are the strongest imaging predictors of malignant non-mass lesions (NMLs) detected on breast US. • A practical system has been created to categorize NMLs found in breast US; each classification is associated with a degree of diagnostic certainty. • The model may contribute to patient stratification by determining the relative likelihood of malignancy and thus support clinical decision-making and evidence-based management.
引用
- Wang X, Jing L, Yan L, et al. A conditional inference tree model for predicting cancer risk of non-mass lesions detected on breast ultrasound. Eur Radiol. 2023. PMID: 38133675. doi:10.1007/s00330-023-10504-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。